



HLA-DO β (M-15): sc-14547

BACKGROUND

Peptide (antigen) binding to major histocompatibility complex (MHC) class II molecules destined for presentation to CD4⁺ helper T cells is determined by two key events. These include the dissociation of class II-associated invariant chain peptides (CLIP) from an antigen binding groove in MHC II- γ dimers and by the activity of MHC molecules HLA-DM and -DO. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM, -DO molecules regulate the dissociation of CLIP and the subsequent binding of exogenous peptides to HLA class II molecules (HLA-DR) by sustaining a conformation that favors peptide exchange. RFLP analysis of HLA-DM genes from rheumatoid arthritis (RA) patients suggests that certain polymorphisms are genetic factors for RA susceptibility.

REFERENCES

1. Kropshofer, H., et al. 1998. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. *EMBO J.* 17: 2971-2981.
2. Siegmund, T., et al. 1999. HLA-DMA and HLA-DMB alleles in German patients with type 1 diabetes mellitus. *Tissue Antigens* 54: 291-294.
3. Arndt, S.O., et al. 2000. Functional HLA-DM on the surface of B cells and immature dendritic cells. *EMBO J.* 19: 1241-1251.
4. Brunet, A., et al. 2000. Functional characterization of a lysosomal sorting motif in the cytoplasmic tail of HLA-DO beta. *J. Biol. Chem.* 275: 37062-37071.
5. Doebele, C.R., et al. 2000. Determination of the HLA-DM interaction site on HLA-DR molecules. *Immunity* 13: 517-527.
6. Louis-Plence, P., et al. 2000. The down-regulation of HLA-DM gene expression in rheumatoid arthritis is not related to their promoter polymorphism. *J. Immunol.* 165: 4861-4869.
7. Toussiro, E., et al. 2000. The association of HLA-DM genes with rheumatoid arthritis in Eastern France. *Hum. Immunol.* 61: 303-308.

CHROMOSOMAL LOCATION

Genetic locus: DOB (human) mapping to 6p21.3; H2-Ob (mouse) mapping to 17 B1.

SOURCE

HLA-DO β (M-15) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the C-terminus of HLA-DO β of mouse origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-14547 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4 $^{\circ}$ C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

HLA-DO β (M-15) is recommended for detection of HLA-DO β of mouse and rat origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz MarkerTM compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz MarkerTM Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruzTM Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.